Vemurafenib for the treatment ofBRAFmutant metastatic melanoma

Differential Effects of the Oncogenic BRAF Inhibitor PLX4032 (Vemurafenib) and its Progenitor PLX4720 on ABCB1 Function

(2016) Martin Michaelis et al.   JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES

Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine

(2014) J.-J. Grob et al.   ANNALS OF ONCOLOGY

New RAF kinase inhibitors in cancer therapy

(2014) Juan Martin-Liberal et al.   EXPERT OPINION ON PHARMACOTHERAPY

Immune Checkpoint Blockade

(2014) Jarushka Naidoo et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

(2014) Grant A McArthur et al.   LANCET ONCOLOGY

Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study

(2014) James Larkin et al.   LANCET ONCOLOGY

Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study

(2014) Antoni Ribas et al.   LANCET ONCOLOGY

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

(2014) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

(2013) Jedd D. Wolchok et al.   Annals of the New York Academy of Sciences

Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study

(2013) Reinhard Dummer et al.   EUROPEAN JOURNAL OF CANCER

B-Raf mutation: A key player in molecular biology of cancer

(2013) M.A. Rahman et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma

(2013) Kerstin Trunzer et al.   JOURNAL OF CLINICAL ONCOLOGY

B-Raf and the inhibitors: from bench to bedside

(2013) Tiangui Huang et al.   Journal of Hematology & Oncology

Which drug, and when, for patients with BRAF-mutant melanoma?

(2013) Sekwon Jang et al.   LANCET ONCOLOGY

Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma

(2013) Geoffrey T. Gibney et al.   Nature Reviews Clinical Oncology

Hepatotoxicity with Combination of Vemurafenib and Ipilimumab

(2013) Antoni Ribas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions

(2013) Alastair J. King et al.   PLoS One

How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma

(2012) J. Wolchok   ANNALS OF ONCOLOGY

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2012) R. Dummer et al.   ANNALS OF ONCOLOGY

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm

(2012) Muhammad Khattak et al.   Therapeutic Advances in Medical Oncology

Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma

(2011) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

BRAF as therapeutic target in melanoma

(2010) Claudia Wellbrock et al.   BIOCHEMICAL PHARMACOLOGY

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

Mutation-driven drug development in melanoma

(2010) Keith T Flaherty et al.   CURRENT OPINION IN ONCOLOGY

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline

(2009) Claus Garbe et al.   EUROPEAN JOURNAL OF CANCER

Final Version of 2009 AJCC Melanoma Staging and Classification

(2009) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY

Melanoma Genetics and Therapeutic Approaches in the 21st Century: Moving from the Benchside to the Bedside

(2008) Thomas L. Hocker et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

(2008) J. Tsai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA